About this trial
Reflux disease can severely impact upon quality-of-life and lead to complications, including ulceration of the oesophagus. It is often controlled with self-help measures and medication. However, sometimes surgery is recommended. The current standard surgical treatment is called a fundoplication. This operation is carried out through keyhole (laparoscopic) surgery, and tightens the lower oesophagus to prevent reflux. Fundoplication is very safe and improves the quality-of-life of most patients. However, many patients have gas bloating, difficulty swallowing and recurrence of their reflux symptoms. As an alternative, some surgeons use a device called LINX, using a keyhole procedure. LINX is a magnetic device that wraps around the lower oesophagus to prevent reflux. Studies suggest that LINX may cause fewer complications, with a similar improvement in quality-of-life. However, there is a need for better evidence to compare LINX with fundoplication in the surgical treatment of reflux disease. GOLF is a multi-centre study designed which to determine if LINX achieves similar reflux control and improves symptoms compared to fundoplication. GOLF measures: (1) quality of life,(2) surgical complications, including need for additional treatment, (3) financial cost-effectiveness and (4) objectively measure the presence of acid that has refluxed into the lower oesophagus. GOLF aims randomise 460 patients to receive fundoplication or the LINX device. It will be conducted across at least 16 UK and 7 European specialist surgical centres. All participants will be followed up at 6 weeks, 6, 12 and 24 months to assess which treatment offers the best results after surgery. A quality assurance programme within participating centres will ensure that procedures are completed to a high-quality standard. Study results will incorporate a patient and public involvement programme, which will inform national and international guidelines for the surgical treatment of reflux disease.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Age 18 years and above
Willing and able to give informed consent
Patients with GORD insufficiently controlled by medical therapy or intolerance to medical therapy being considered for anti-reflux surgery
Symptomatic and objectively defined GORD; endoscopy with appearances or biopsies consistent with reflux oesophagitis, or 24-hour pH study or BRAVO test of the oesophagus consistent with GORD
Disqualifiers
Unsuitable for surgical intervention due to medical conditions precluding general anaesthesia
Suspected or known allergies to titanium, stainless steel, nickel, or ferrous materials
Previous anti-reflux or gastric surgery
Previous or planned neurosurgical intervention
Trial design
Parallel
Treatments tested in this trial
Laparoscopic or robotic LINX procedure
Procedure/SurgeryParticipants randomised to laparoscopic or robotic magnetic sphincter augmentation (LINX procedure) will receive surgical treatment under general anaesthesia, with placement of the LINX device around the distal oesophagus. The LINX device comprises titanium beads with magnets in the centre.
Laparoscopic or robotic fundoplication
Procedure/SurgeryParticipants randomised to laparoscopic or robotic fundoplication will receive surgical treatment for managing GORD including a total or partial fundic wrap behind or in front of the distal oesophagus and gastro-oesophageal junction.
Treatment groups
Trial outcomes
Primary outcomes
Symptomatic GORD and health-related quality of life (HRQL) assessed using the GORD-HRQL questionnaire
Secondary outcomes
Prevalence of gas bloating measured using participant-reported outcomes/GORD-HRQL and Foregut Symptom Questionnaire
Prevalence of inability to belch measured using participant-reported outcomes/GORD-HRQL and Foregut Symptom Questionnaire
Prevalence of symptomatic GORD, inability to belch and gas bloating measured using participant-reported outcomes/GORD-HRQL and Foregut Symptom Questionnaire
Severity of dysphagia and regurgitation measured using participant-reported outcomes/GORD-HRQL questionnaire
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
University of Oxford
Lead sponsor
King's College London
Collaborator
Imperial College London
Collaborator
Oxford University Hospitals NHS Trust
Collaborator
Guy's and St Thomas' NHS Foundation Trust
Collaborator
University of Bristol
Collaborator
University of Southampton
Collaborator